| ABTT34 Stock | | | BRL 58.26 0.18 0.31% |
President
Mr. Andrew H. Lane is Senior Vice President Established Pharmaceuticals, Emerging Markets of the Company. From 2014 to 2015 served with Divisional Vice President, Established Pharmaceuticals, Asia Pacific. Between 2011 to 2014 Lane is Vice President, Asia Pacific, Takeda Pharmaceutical Company Limited . since 2017.
| Age | 48 |
| Tenure | 7 years |
| Phone | 224 667 6100 |
| Web | https://www.abbott.com |
Abbott Laboratories Management Efficiency
The company has return on total asset
(ROA) of
0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.
Abbott Laboratories has accumulated 17.3
B in total debt with debt to equity ratio
(D/E) of 0.55, which is about average as compared to similar companies. Abbott Laboratories has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Abbott Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Abbott Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbott Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbott to invest in growth at high rates of return. When we think about Abbott Laboratories' use of debt, we should always consider it together with cash and equity.
Similar Executives
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company was founded in 1888 and is based in North Chicago, Illinois. ABBOTT DRN operates under Medical Devices classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 109000 people. Abbott Laboratories (ABTT34) is traded on Sao Paulo Exchange in Brazil and employs 115,000 people.
Management Performance
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Scott, Independent Director | |
| Christopher Scoggins, Senior Vice President - Rapid Diagnostics | |
| Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | |
| Mary Moreland, Executive Vice President of Human Resources | |
| Roger Bird, Senior Vice President - U.S. Nutrition | |
| Michael Dale, Senior Vice President - Structural Heart | |
| Nancy McKinstry, Independent Director | |
| Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets | |
| Phebe Novakovic, Independent Director | |
| Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets | |
| Roxanne Austin, Independent Director | |
| Sally Blount, Independent Director | |
| Randel Woodgrift, Senior Vice President - CRM | |
| Daniel Starks, Independent Director | |
| Michelle Kumbier, Independent Director | |
| Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure | |
| Lisa Earnhardt, Executive Vice President - Medical Devices | |
| John Capek, Executive Vice President - Ventures | |
| Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America | |
| Robert Alpern, Independent Director | |
| Miles White, Chairman, CEO and Chairman of Executive Committee | |
| Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director | |
| Glenn Tilton, Independent Director | |
| Elaine Leavenworth, VP Officer | |
| Darren McDew, Independent Director | |
| Charles Brynelsen, Senior Vice President - Abbott Vascular | |
| Edward Liddy, Independent Director | |
| Hubert Allen, Executive Vice President, General Counsel, Secretary | |
| John Stratton, Independent Director | |
| Joseph Manning, Senior Vice President - Abbott Nutrition International | |
| Scott Leinenweber, Licensing Relations | |
| James Young, VP Officer | |
| John Ginascol, Executive Vice President - Core Diagnostics | |
| Jared Watkin, Senior Vice President - Diabetes Care | |
| William Osborn, Lead Independent Director | |
| Robert Funck, Chief Financial Officer, Executive Vice President - Finance | |
| Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America. | |
| Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics | |
| Melissa Brotz, VP Marketing | |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Abbott Stock
When determining whether Abbott Laboratories is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Abbott Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Abbott Laboratories Stock.
Highlighted below are key reports to facilitate an investment decision about Abbott Laboratories Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For information on how to trade Abbott Stock refer to our
How to Trade Abbott Stock guide.
You can also try the
AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abbott Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.